癌症研究的生物信息学资源

随着癌症研究的发展,生物信息学成为癌症研究的一个非常重要的方法和手段,本文从微阵列芯片数据管理和分析软件、微阵列数据仓库、蛋白质功能预测工具和蛋白质结构预测工具等四个方面介绍癌症研究的生物信息学资源信息,以给相关研究提供帮助.     

阵列光镊与微流控芯片技术的结合与应用

在生物医学研究领域中,阵列光镊与微流控芯片的结合已经成为进行细胞操纵、转移以及少量细胞样品分选等方面最有希望的方法之一。光镊技术对样品具有非接触弹性控制、无机械损伤、可无菌操作等优势,以及微流控芯片分析的高效、多功能、微型化、低成本等优势,成为芯片实验室(Lab-on-a-Chip)的重要研究方面。该文概述了阵列光镊技术的形成与研究现状以及微流控芯片技术的发展与应用现状,分析了在不同阵列光镊形成方法下结合微流控芯片可实现的功能与应用,并对其发展趋势进行了展望。     

抗体芯片技术及其在寄生虫研究中的应用

随着蛋白质组学相关技术的深入发展,使病原体入侵与宿主间相互作用的研究越来越深入,蛋白质互作和蛋白质表达模式的高通量、大规模分析成为可能。通过其技术对蛋白质进行系统分析和鉴定,对疾病的发生发展具有很高的参考价值。抗体芯片分析蛋白质以其微型集成化、大规模化和高通量化的优点,广泛被应用于生物医学领域。对抗体芯片技术目前的研究进展及其在寄生虫研究方面的应用进行了阐述。寄生虫具有独特的发育过程,其不同发育阶段表达虫体蛋白及排泄分泌产物具有很大差异,将抗体芯片技术应用于寄生虫蛋白质组学研究,对特异性标识抗原筛选,探索寄生虫生长发育、定植入侵、免疫逃避和免疫抑制等具有重要意义,为寄生虫病的早期诊断及治疗,寻找新的药物靶点等奠定基础。同时,为寄生虫蛋白质组学进一步研究提供新的思路和方法。     

蛋白质芯片在肿瘤血清标识物发现中的应用

蛋白质芯片是一种新型的高通量蛋白质组学技术,由于其具有高通量、微型化、可平行快速分析等优点,因此在肿瘤血清标识物发现研究方面具有广泛的应用前景。本文综述了蛋白质芯片的基本原理、类型及其在肿瘤血清标记物发现研究中的应用,将蛋白质芯片技术与传统的肿瘤标志物发现技术进行了比较,并对蛋白质芯片技术在肿瘤标识物发现研究上的进一步应用进行了展望。     

蛋白质芯片构建技术进展

蛋白质芯片是一项实现蛋白质高通量分析和检测的新型技术,在生命科学的各个领域具有重要的应用前景。但是由于蛋白质本身的敏感性质和芯片的独特结构,蛋白质芯片技术的发展面临许多难点,这些正是蛋白质芯片研究者需要共同讨论的问题。本文从芯片构造、探针的固定方法和检测方法三个方面对芯片的构造进行分析和讨论,并对其相关技术的进展进行综述。     

蛋白质芯片在蛋白质组学研究中的作用

蛋白质芯片是以高度并行性、高通量、微型化和自动化为特点的蛋白质组检测技术。本文综述了蛋白质芯片在蛋白质组学研究中的多种作用,包括普通蛋白质芯片在微量蛋白质分离、蛋白质与蛋白质之间以及蛋白质与其他小分子间相互作用和蛋白质定量检测方面的作用,普通蛋白质芯片通过与质谱技术、生物传感器技术的结合而拓展其应用范围,以及蛋白质组芯片、活性的蛋白质芯片在蛋白质组学研究中应用的进展。     

无细胞系统原位制备蛋白质芯片片及其应用

主要介绍了目前在生物芯片表面进行蛋白质无细胞表达与定向制备蛋白质芯片的研究进展,包括各种基因植入芯片的方法、蛋白质体外不同表达的途径、蛋白质固定的策略以及可能的应用发展前景等.蛋白质芯片以其高通量、高灵敏和检测迅速等优点正成为蛋白质组学研究中的重要工具之一.蛋白质的高效表达与纯化、蛋白质在芯片表面的有效固定与蛋白质活性的保持等内容是蛋白质芯片技术发展的关键.采用纳米生物技术与无细胞表达系统,已经可以在生物芯片表面通过植入基因的方式制备相关的蛋白质芯片,从而为蛋白质芯片的原位制备开辟了新的方向.     

蛋白质芯片技术

以前对蛋白质的研究集中在一次研究一种蛋白质 ,通常费时费力 ;而蛋白质芯片技术是研究蛋白质组的新技术 ,是高通量、微型化和自动化的蛋白质分析技术。它可以用来研究蛋白质的亚细胞定位和蛋白质与蛋白质之间的相互作用 ,以及对蛋白质的功能进行生物化学分析 ,将对蛋白质组研究及医学生物学的发展有很大的推动作用。较系统地介绍了蛋白质芯片的概念、制作及检测方法 ;同时也讨论了蛋白质芯片的两种功能形式、存在问题和应用前景。     

新书介绍

科学出版社生命科学编辑部新书推介“反爆炸、生物、化学、核与辐射恐怖活动的科学技术问题和对策研究”丛书蛋白质芯片(影印版)Protein M icroarraysM ark Schena7-03-014321-3/Q.14762005.565元生物芯片技术是一种高通量检测技术,它包括基因芯片、蛋白芯片及芯片实验室三大领域。蛋白质芯片以蛋白质代替DNA作为检测目的物,比基因芯片更接近生命活动的物质层面,能直接测定蛋白质的相对水平及与其他分子的交互作用情况,以定量化的方式反映基因的活动情况,因而蛋白质芯片有着比基因芯片更加直接的应用前景。本书对蛋白质芯片技术进行了全…     

科学出版社生命科学编辑部新书推介

蛋白质芯片(影印版)Protein M icroarraysMark Schena7-03-014321-3/Q.14762005.565元生物芯片技术是一种高通量检测技术,它包括基因芯片、蛋白芯片及芯片实验室三大领域.蛋白质芯片以蛋白质代替DNA作为检测目的物,比基因芯片更接近生命活动的物质层面,能直接测定蛋白质的相对水平及与其他分子的交互作用情况,以定量化的方式反映基因的活动情况,因而蛋白质芯片有着比基因芯片更加直接的应用前景.本书对蛋白质芯片技术进行了全面细致的阐述,包括技术原理、生产方法、表面化学、检测策略,以及抗原、抗体数据分析,同时全书图文并茂,提供了…     

Biosynthesis of mini-antibodies to human ferritin in plant and bacterial producers

A recombinant scFv antibody against human spleen ferritin was expressed as a barstar-fused protein in Escherichia coli and in Nicotiana tabacum plants and suspension cell cultures. As demonstrated by immunoblotting with antibarstar antibodies, direction of the recombinant protein to the endomembrane system of plant cells ensured its stability and solubility. Production of the recombinant protein did not differ between parental transgenic plants and their first-generation progeny. Fusion with barstar allowed not only immunochemical detection of the recombinant scFv antibody, but also their purification from the plant material by affinity chromatography with barnase-His6 immobilized on a metal-affinity carrier.     

Diagnostic and analytical applications of protein microarrays

DNA microarrays have changed the field of biomedical sciences over the past 10 years. For several reasons, antibody and other protein microarrays have not developed at the same rate. However, protein and antibody arrays have emerged as a powerful tool to complement DNA microarrays during the past 5 years. A genome-scale protein microarray has been demonstrated for identifying protein–protein interactions as well as for rapid identification of protein binding to a particular drug. Furthermore, protein microarrays have been shown as an efficient tool in cancer profiling, detection of bacteria and toxins, identification of allergen reactivity and autoantibodies. They have also demonstrated the ability to measure the absolute concentration of small molecules. Besides their capacity for parallel diagnostics, microarrays can be more sensitive than traditional methods such as enzyme-linked immunosorbent assay, mass spectrometry or high-performance liquid chromatography-based assays. However, for protein and antibody arrays to be successfully introduced into diagnostics, the biochemistry of immunomicroarrays must be better characterized and simplified, they must be validated in a clinical setting and be amenable to automation or integrated into easy-to-use systems, such as micrototal analysis systems or point-of-care devices.     

Diagnostic and analytical applications of protein microarrays

DNA microarrays have changed the field of biomedical sciences over the past 10 years. For several reasons, antibody and other protein microarrays have not developed at the same rate. However, protein and antibody arrays have emerged as a powerful tool to complement DNA microarrays during the past 5 years. A genome-scale protein microarray has been demonstrated for identifying protein-protein interactions as well as for rapid identification of protein binding to a particular drug. Furthermore, protein microarrays have been shown as an efficient tool in cancer profiling, detection of bacteria and toxins, identification of allergen reactivity and autoantibodies. They have also demonstrated the ability to measure the absolute concentration of small molecules. Besides their capacity for parallel diagnostics, microarrays can be more sensitive than traditional methods such as enzyme-linked immunosorbent assay, mass spectrometry or high-performance liquid chromatography-based assays. However, for protein and antibody arrays to be successfully introduced into diagnostics, the biochemistry of immunomicroarrays must be better characterized and simplified, they must be validated in a clinical setting and be amenable to automation or integrated into easy-to-use systems, such as micrototal analysis systems or point-of-care devices.     

Local and global anatomy of antibody‐protein antigen recognition

Deciphering antibody‐protein antigen recognition is of fundamental and practical significance. We constructed an antibody structural dataset, partitioned it into human and murine subgroups, and compared it with nonantibody protein‐protein complexes. We investigated the physicochemical properties of regions on and away from the antibody‐antigen interfaces, including net charge, overall antibody charge distributions, and their potential role in antigen interaction. We observed that amino acid preference in antibody‐protein antigen recognition is entropy driven, with residues having low side‐chain entropy appearing to compensate for the high backbone entropy in interaction with protein antigens. Antibodies prefer charged and polar antigen residues and bridging water molecules. They also prefer positive net charge, presumably to promote interaction with negatively charged protein antigens, which are common in proteomes. Antibody‐antigen interfaces have large percentages of Tyr, Ser, and Asp, but little Lys. Electrostatic and hydrophobic interactions in the Ag binding sites might be coupled with Fab domains through organized charge and residue distributions away from the binding interfaces. Here we describe some features of antibody‐antigen interfaces and of Fab domains as compared with nonantibody protein‐protein interactions. The distributions of interface residues in human and murine antibodies do not differ significantly. Overall, our results provide not only a local but also a global anatomy of antibody structures.     

Biosynthesis of the scFv Antibody to Human Ferritin in Plant and Bacterial Producers

A recombinant scFv antibody against human spleen ferritin was expressed as a barstar-fused protein in Escherichia coli and in Nicotiana tabacum plants and suspension cell cultures. As demonstrated by immunoblotting with antibarstar antibodies, direction of the recombinant protein to the endomembrane system of plant cells ensured its stability and solubility. Production of the recombinant protein did not differ between parental transgenic plants and their first-generation progeny. Fusion with barstar allowed not only immunochemical detection of the recombinant scFv antibody, but also their purification from the plant material by affinity chromatography with barnase-His₆ immobilized on a metal-affinity carrier.     

Co-expression of Skp and FkpA chaperones improves cell viability and alters the global expression of stress response genes during scFvD1.3 production

Background  

The overexpression of scFv antibody fragments in the periplasmic space of Escherichia coli frequently results in extensive protein misfolding and loss of cell viability. Although protein folding factors such as Skp and FkpA are often exploited to restore the solubility and functionality of recombinant protein products, their exact impact on cellular metabolism during periplasmic antibody fragment expression is not clearly understood. In this study, we expressed the scFvD1.3 antibody fragment in E. coli BL21 and evaluated the overall physiological and global gene expression changes upon Skp or FkpA co-expression.     

Rat sulfite oxidase antibodies cross-react with two gene family-related proteins: albumin and vitamin D-binding protein.

Screening lambda cDNA libraries from rat liver with antibody to native rat liver sulfite oxidase (RLSO) showed cross-reaction with two proteins that belong to the same gene family: serum albumin and vitamin D-binding protein. Antibodies raised against native RLSO or sodium dodecyl sulfate-denatured protein cross-reacted with these proteins by Western blot analysis. The relative effectiveness of RLSO antibody binding was estimated to be 1/5 for rat serum albumin and 1/10 for rat vitamin D-binding protein. This result was not caused by contaminating proteins in the RLSO used for immunization as the RLSO preparation did not react with rat serum albumin antibody. RLSO antibodies, selected for their ability to bind rat serum albumin immobilized on nitrocellulose, recognized both rat serum albumin and RLSO. RLSO antibody, with albumin-reactive antibody removed, still recognized vitamin D-binding protein, suggesting that multiple determinants specific to each protein are involved in the cross-reaction. Comparison of RLSO antibody binding to the rat and human proteins indicated that the determinants were species-specific. cDNA clones identified by screening cDNA libraries with RLSO antibody demonstrated that these determinants reside in the C-terminal domain of these proteins. These results suggest that these proteins contain some common immunological features and may be evolutionarily related.     

褐飞虱细胞色素P450基因CYP4C62的原核表达及多克隆抗体的制备

【目的】细胞色素P450单加氧酶在昆虫生长发育和适应环境过程中发挥着重要功能。【方法】本研究克隆了褐飞虱Nilaparvata lugens细胞色素P450基因CYP4C62的开放阅读框（不含信号肽编码序列部分）,在大肠杆菌Escherichia coli中实现了高效表达,经Ni-NTA琼脂糖凝胶亲和层析柱纯化得到了重组的CYP4C62蛋白。将该蛋白免疫日本大耳白兔Oryctolagus cuniculus雄兔,制备了兔抗CYP4C62血清抗体。采用间接ELISA方法检测了血清抗体的效价;并通过Western印迹杂交检测了该抗体的免疫学特异性。【结果】结果表明,通过大肠杆菌表达出的CYP4C62蛋白相对分子量为56 kD。间接ELISA法检测表明,制备的兔抗CYP4C62抗体的效价达到1∶100 000。Western印迹杂交证实,该抗体既可与异源表达的CYP4C62蛋白特异性结合,也可以与褐飞虱总蛋白中内源的CYP4C62特异性结合,表明具有较好的免疫反应特异性。【结论】CYP4C62多克隆抗体的成功制备,为后续分析CYP4C62在褐飞虱各组织中的时空表达水平,并通过免疫组织化学法定位分析该蛋白的组织、细胞及亚细胞分布规律,及最终解析CYP4C62的生物学功能奠定了基础。     

Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils

A single-domain fragment, cAb-HuL22, of a camelid heavy-chain antibody specific for the active site of human lysozyme has been generated, and its effects on the properties of the I56T and D67H amyloidogenic variants of human lysozyme, which are associated with a form of systemic amyloidosis, have been investigated by a wide range of biophysical techniques. Pulse-labeling hydrogen-deuterium exchange experiments monitored by mass spectrometry reveal that binding of the antibody fragment strongly inhibits the locally cooperative unfolding of the I56T and D67H variants and restores their global cooperativity to that characteristic of the wild-type protein. The antibody fragment was, however, not stable enough under the conditions used to explore its ability to perturb the aggregation behavior of the lysozyme amyloidogenic variants. We therefore engineered a more stable version of cAb-HuL22 by adding a disulfide bridge between the two beta-sheets in the hydrophobic core of the protein. The binding of this engineered antibody fragment to the amyloidogenic variants of lysozyme inhibited their aggregation into fibrils. These findings support the premise that the reduction in global cooperativity caused by the pathogenic mutations in the lysozyme gene is the determining feature underlying their amyloidogenicity. These observations indicate further that molecular targeting of enzyme active sites, and of protein binding sites in general, is an effective strategy for inhibiting or preventing the aberrant self-assembly process that is often a consequence of protein mutation and the origin of pathogenicity. Moreover, this work further demonstrates the unique properties of camelid single-domain antibody fragments as structural probes for studying the mechanism of aggregation and as potential inhibitors of fibril formation.